ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (18)
2023
-
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388
-
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1497-1505
2021
-
Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors
Cancers, Vol. 13, Núm. 15
-
Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial
Clinical Cancer Research, Vol. 27, Núm. 10, pp. 2890-2898
-
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
Scientific Reports, Vol. 11, Núm. 1
-
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 988-1000
-
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11
2020
-
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma
Translational Oncology, Vol. 13, Núm. 7
-
Genetic profile and functional proteomics of anal squamous cell carcinoma: Proposal for a molecular classification
Molecular and Cellular Proteomics, Vol. 19, Núm. 4, pp. 690-700
2019
-
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)
Scientific Reports
-
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Scientific Reports, Vol. 9, Núm. 1
2017
2015
-
Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Revista Espanola de Patologia
-
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273
2014
-
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer
Oncologist, Vol. 19, Núm. 4, pp. 350-351
-
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma
Cancer
2013
2012
-
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
Clinical and Translational Oncology, Vol. 14, Núm. 8, pp. 606-612